AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...
GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...
IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...
First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab&rs...
Abbisko announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically si...
IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...
Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agree...
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...
GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing applica...
Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...
Agilent Technologies Inc. (NYSE: A) announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infi...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...
© 2024 Biopharma Boardroom. All Rights Reserved.
